Dr. Trent Wang (IMAGE)

University of Miami Miller School of Medicine

Dr. Trent Wang

Caption

A study led by researchers at Sylvester Comprehensive Cancer Center and presented by hematologist Trent Wang, D.O., at ASH 2023 suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

Credit

Clutch Content Partners

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.